Stocks and Markets Podcast: Strategist gives tips on what to watch for in August

Freedom Capital Markets' Jay Woods advises investors to prepare for a "garden variety pullback" in August and September, historically weak months despite recent strong market performance where the S&P 500 gained 32.2% from April lows. He recommends buying dips in robust sectors like technology and financials, while cautioning against pharmaceuticals, staples, and some materials due to anticipated margin pressures and regulatory concerns. Woods forecasts a strong fourth quarter, with markets potentially reaching new highs by 2025 after this period of digestion.

Analysis

The market is currently navigating a seasonal period of weakness, with August and September historically being underperforming months. According to Jay Woods of Freedom Capital Markets, this is a "garden variety pullback" and a healthy "digestive phase" following a significant market rally where the S&P 500 rose 32.2% and the Nasdaq 45% from their April lows. Despite a largely better-than-expected earnings season, high-flying technology stocks like Microsoft (MSFT), Nvidia (NVDA), and Meta (META) are showing signs of consolidation after their substantial gains. The strategist's outlook remains optimistic, forecasting a strong fourth quarter and potential new highs in 2025, suggesting this pullback is a buying opportunity. Specific sector guidance recommends focusing on technology and financials as market drivers while avoiding sectors with distinct headwinds. The pharmaceutical industry faces margin compression risk from potential U.S. drug price controls. Consumer staples, including Procter & Gamble (PG) and Clorox (CLX), are also expected to see margin pressure, likely benefiting discount retailers like Dollar General (DG) and Dollar Tree (DLTR). In the materials sector, companies like Sherwin-Williams (SHW) and Dow (DOW) are flagged as problematic after repeatedly lowering guidance, placing them "in the penalty box."

Key Decisions for Investors

• Prepare to capitalize on the anticipated seasonal pullback by identifying buying opportunities on dips in robust technology and financial sector leaders.
• Reduce or avoid exposure to the pharmaceuticals sector due to significant margin risk from potential government drug pricing reforms and underweight consumer staples (PG, CLX, KMB) on similar margin concerns.
• Exercise caution with materials stocks like SHW and DOW that have issued consecutive warnings, and consider rotating capital within the consumer space from staples to discount retailers (DG, DLTR) to align with shifting consumer behavior.
• Monitor large-cap technology stocks like Microsoft for attractive entry points as they undergo a period of price consolidation following their recent substantial outperformance.